nach oben

Erschienen in:

2017 | OriginalPaper | Buchkapitel

2. Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie

verfasst von : Prof. Dr. Gerhard Glatting, PD Dr. rer.nat. Carmen Wängler, Prof. Dr. rer. nat. Björn Wängler

Erschienen in: MR- und PET-Bildgebung der Prostata

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Im Gegensatz zu anderen bildgebenden Verfahren, welche zuvorderst die Anatomie des Patienten wiedergeben, stellt die PET eine Methode der Funktionsdiagnostik dar. Kapitel 2.1 stellt die physikalisch-technischen Grundlagen der PET vor. Dabei werden neben dem PET-Prinzip auch die eingesetzten Radionuklide, deren Eigenschaften und Herstellung, sowie Detektoren, Bildqualität sowie Akquisitions- und Auswertestrategien referiert. Die funktionelle Bildgebung des Prostatakarzinoms mittels PET ist in der Lage, die Erkrankung frühzeitig, sensitiv und spezifisch mittels verschiedener Mechanismen zu visualisieren und ist damit ein wertvolles Werkzeug für die primäre sowie Rezidivdiagnostik, die Einschätzung der Tumoraggressivität und des Therapieansprechens. Für die PET-Bildgebung des Prostatakarzinoms sind verschiedene Klassen von Radiotracern verfügbar, die eine unterschiedliche Eignung für die klinische Bildgebung der Erkrankung aufweisen. Kapitel 2.2 diskutiert die wichtigsten dieser Radiotracer.

Abiraj K, Mansi R, Tamma ML, Fani M, Forrer F, Nicolas G, Cescato R, Reubi JC, Maecke HR (2011) Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Journal of Nuclear Medicine 52:1970–1978

Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015) The diagnostic value of PET-CT imaging with the Ga-68-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 42:197–209

Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013) PET imaging with a [Ga-68]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. European Journal of Nuclear Medicine and Molecular Imaging 40:486–395

Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014) Comparison of PET imaging with a Ga–68-labelled PSMA ligand and F–18-choline-based PET-CT for the diagnosis of recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:11–20

Akin O, Hricak H (2007) Imaging of prostate cancer. Radiologic Clinics of North America 45:207–222

Alt K, Wiehr S, Ehrlichmann W, Reischl G, Wolf P, Pichler BJ, Esaesser-Beile U, Buhler P (2010) High-resolution animal PET imaging of prostate cancer xenografts with three different Cu–64-labeled antibodies against native cell-adherent PSMA. Prostate 70:1413–1421

Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52:42s–55s

Ananias HJK, De Jong IJ, Dierckx RA, van de Wiele C, Helfrich W, Elsinga PH (2008) Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 14:3033–3047

Ananias HJK, van den Heuvel MC, Helfrich W, de Jong IJ (2009) Expression of the Gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69:1101–1108

Apolo AB, Pandit-Taskar N, Morris MJ (2008) Novel Tracers and Their Development for the Imaging of Metastatic prostate cancer. Journal of Nuclear Medicine 49:2031–2041

Asano Y, Inoue Y, Ikeda Y, Kikuchi K, Hara T, Taguchi C, Tokushige T, Maruo H, Takeda T, Nakamura T, Fujita T, Kumagai Y, Hayakawa K (2011) Phase I clinical study of NMK36: a new PET tracer with the synthetic amino acid analogue anti-[F–18]FACBC. Annals of Nuclear Medicine 25:414–318

Badin JR, Shied AF (2008) Imaging of cell proliferation: Status and prospects. Journal of Nuclear Medicine 49:64s–80s

Bandari RP, Jiang ZR, Reynolds TS, Bernskoetter NE, Szczodroski AF, Bassuner KJ, Kirkpatrick DL, Rold TL, Sieckman GL, Hoffman TJ, Connors JP, Smith CJ (2014) Synthesis and biological evaluation of copper-64 radiolabeled [DUPA–6-Ahx-(NODAGA)–5-Ava-BBN(7–14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer. Nuclear Medicine and Biology 41:355–363

Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ (2005) Phase I trial of (177)lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 23:4591–3601

Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ (2003) Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. Journal of Urology 170:1717–1721

Banerjee SR, Foss CA, Pullambhatla M, Wang YC, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG (2015) Preclinical Evaluation of Y–86-labeled inhibitors of prostate specific membrane antigen for dosimetry estimates. Journal of Nuclear Medicine 56:628–634

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG (2010) Ga-68-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. Journal of Medicinal Chemistry 53:5333–5341

Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Erson CJ, Mease RC, Pomper MG (2014) Cu-64-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. Journal of Medicinal Chemistry 57:2657–2669

Barinka C, Byun Y, Dusich CL, Banerjee SR, Chen Y, Castanares M, Kozikowski AP, Mease RC, Pomper MG, Lubkowski J (2008) Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization. Journal of Medicinal Chemistry 51:7737–7743

Barinka C, Rovenska M, Mlcochova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J, Lubkowski J (2007) Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II. Journal of Medicinal Chemistry 50:3267–3273

Beattie BJ, Smith-Jones PM, Jhanwar YS, Schoder H, Schmidtlein CR, Morris MJ, Zanzonico P, Squire O, Meirelles GSP, Finn R, Namavari M, Cai SD, Scher HI, Larson SM, Humm JL (2010) Pharmacokinetic Assessment of the Uptake of 16 beta-F-18-Fluoro-5 alpha-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET. Journal of Nuclear Medicine 51:183–192

Beheshti M, Hai S, Zakav R, Steinmai M, Waldenberge P, Kuni T, Nade M, Langstege W, Loid, W (2013a) Impact of F-18-Choline PET-CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics. Journal of Nuclear Medicine 54:833–884

Beheshti M, Imamovic, L, Broinger G, Vali R, Waldenberger P, Stoiber F, Nader M, Gruy B, Janetschek G, Langsteger W (2010) F-18 Choline PET-CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 254:925–933

Beheshti M, Langsteger W, Sommerhuber A, Steinmair M, Wolf I, Valencia R, Lesche R, Nader M, Piert M, Loidl W (2012) BAY 1075553 PET-CT in staging and re-staging of prostate cancer patients – phase I study and comparison to ¹⁸F-FCH. Journal of Nuclear Medicine 53:272

Beheshti M, Treglia G, Zakavi R, Langsteger W, Ghodsi RMA, Dabbagh KVR, Sadeghi R (2013b) Application of ¹¹C-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature. Bju International 112:1062–1072

Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, Haberkorn U, Kopka K, Eder M (2015) Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. Journal of Nuclear Medicine 56:914–920

Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S (2003) Dual-modality PET-CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 30 (4):588–596

Beyer T, Rosenbaum S, Veit P, Stattaus J, Müller SP, DiFilippo FP, Schöder H, Mawlawi O, Roberts F, Bockisch A, Kühl H (2005) Respiration artifacts in whole-body ¹⁸F-FDG PET-CT studies with combined PET-CT tomographs employing spiral CT technology with 1 to 16 detector rows. Eur J Nucl Med Mol Imaging 32 (12):1429–1439. doi:10.1007/s00259–005–1879–8

Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, Jerin J, Young J, Byars L, Nutt R (2000) A combined PET-CT scanner for clinical oncology. J Nucl Med 41 (8):1369–1379

Birtle AJ, Freeman A, Masters JRW, Payne HA, Harland SJ, Registr BSOC (2005) Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < 10 ng/ml. Bju International 96:303–307

Bollinen VR, Krame GM, Jansm EP, Li Y, Oye WJ (2016) A systematic review on [F]FLT-PET uptake as a measure of treatment response in cancer patients. European Journal of Cancer 55:81–97

Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma - A study of 184 cases. Cancer 82:2256–2261

Brogsitter C, Zophel K, Kotzerke J (2013) F-18-Choline, C-11-choline and C-11-acetate PET-CT: comparative analysis for imaging prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 40:S18–S27

Brooks RA, Di Chiro G (1976) Principles of computer assisted tomography (CAT) in radiographic and radioisotopic imaging. Phys Med Biol 21 (5):689–732

Brownell GL (1999) A History of Positron Imaging. Physics Research Laboratory, Massachusetts General Hospital, Division of Radiological Sciences, Massachusetts Institute of Technology. S1–11

Burger C, Goerres G, Schoenes S, Buck A, Lonn AH, Von-Schulthess GK (2002) PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging 29 (7):922–927

Carlucci G, Kuipers A, Ananias HJK, Faria DD, Dierckx RAJO, Helfrich W, Rink R, Moll GN, de Jong IJ, Elsinga PH (2015) GRPR-selective PET imaging of prostate cancer using [F-18]-bombesin analogs. Peptides 67:45–54

Casey ME, Nutt R (1986) Multicrystal two dimensional BGO detector systems for positron emission tomography. IEEE Trans Nucl Sci 33:469–363

Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini I (2015) Ga-68-PSMA PET-CT for restaging recurrent prostate cancer: which factors are associated with PET-CT detection rate? European Journal of Nuclear Medicine and Molecular Imaging 42:1284–1294

Cescato R, Maina T, Nock B, Nikolopoulou A, Charalambidis D, Piccand V, Reubi JC (2008) Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 49:318–326

Chang SS, O’Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB (1999a) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clinical Cancer Research 5:2674–2681

Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB (1999b) Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Research 59:3192–3198

Chang SS, Reuter VE, Heston WDW, Gaudin PB (2001) Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology 57:801–805

Chatalic KLS, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M (2014) Preclinical comparison of (AlF)-F-18- and Ga-68-labeled Gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer. Journal of Nuclear Medicine 55:2050–2056

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambahatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. Journal of Medicinal Chemistry 51:7933–7943

Chen Y, Pullambhatla M, Banerjee SR, Byun Y, Stathis M, Rojas C, Slusher BS, Mease RC, Pomper MG (2012) Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen. Bioconjugate Chemistry 23:2377–2385

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG (2011) 2-(3-{1-Carboxy–5-[(6-[F-18]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic acid, [F-18]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clinical Cancer Research 17:7645–7653

Cherry SR, Sorenson JA, Phelps ME (2012) Physics in Nuclear Medicine. 4th edition Aufl. Elsevier Saunders, Philadelphia PA19103–2899

Chikkaveeraiah BV, Bhirde A, Malhotra R, Patel V, Gutkind JS, Rusling JF (2009) Single-Wall Carbon Nanotube Forest Arrays for Immunoelectrochemical Measurement of Four Protein Biomarkers for prostate cancer. Analytical Chemistry 81:9129–9134

Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG (2012) Biodistribution, tumor detection, and radiation dosimetry of F-18-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. Journal of Nuclear Medicine 53:1883–1891

Cimitan M, Bortolu R, Morassu S, Canzonier V, Garbegli A, Baresi T, Borsatt, E, Drig A, Trov MG (2006) [F-18]fluorocholine PET-CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. European Journal of Nuclear Medicine and Molecular Imaging 33:1387–1390

Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion. EJNMMI Phys 3:8

Conti M, Eriksson L (2016) Physics of pure and non-pure positron emitters for PET: a review and a discussion.« EJNMMI Physics 3(1): 1–17

Conway RE, Petrovic N, Li Z, Heston W, Wu DQ, Shapiro LH (2006) Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Molecular and Cellular Biology 26:5310–5324

Cornelio DB, Roesler R, Schwartsmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Annals of Oncology 18:1457–1466

D’Asseler Y, Vandenberghe S, Winter FD, Van de Walle R, Koole M, Bouwens L, Lemahieu I, Dierckx RA (2001) PET imaging using gamma cameras. Computerized Medical Imaging and Graphics 25 (2):87–96. doi:10.1016/s0895–6111(00)00058–6

Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849

Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ (2005) Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proceedings of the National Academy of Sciences of the United States of America 102:5981–5986

De Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) Preoperative staging of pelvic lymph nodes in prostate cancer by C-11-choline PET. Journal of Nuclear Medicine 44:331–335

Dehdashti F, Picus J, Michalski JM, Dence CS, Siegel BA, Katzenellenbogen JA, Welch MJ (2005) Positron tomographic assessment of androgen receptors in prostatic carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 32:344–350

Demirkol MO, Acar O, Ucar B, Ramazanoglu SR, Saglican Y, Esen T (2015) prostate-specific membrane antigen-based imaging in prostate cancer: Impact on Clinical Decision Making Process. Prostate 75:748–757

Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomacker K, Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S, Drzezga A, Neumaier B (2015) Comparison of [F-18]DCFPyL and [Ga-68]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Molecular Imaging and Biology 17:575–584

Durkan K, Jiang ZR, Rold TL, Sieckman GL, Hoffman TJ, Bandari RP, Szczodroski AF, Liu LQ, Miao YB, Reynolds TS, Smith CJ (2014) A heterodimeric [RGD-Glu-[Cu–64-NO2A]–6-Ahx-RM2] alpha(v)beta(3)/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nuclear Medicine and Biology 41:133–139

Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, Graner FP, Kubler H, Haberhorn U, Eisenhut M, Wester HJ, Gschwend JE, Schwaiger M (2015) Evaluation of hybrid Ga-68-PSMA ligand PET-CT in 248 patients with biochemical recurrence after radical prostatectomy. Journal of Nuclear Medicine 56:668–674

Eder M, Schafer M, Bauder-Wust U, Haberkorn U, Eisenhut M, Kopka, K (2014) Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. Prostate 74:659–668

Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M (2012) Ga–68-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging. Bioconjugate Chemistry 23:688–697

Effert PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G (1996) Metabolic imaging of untreated prostate cancer by positron emission tomography with (18)fluorine-labeled deoxyglucose. Journal of Urology 155:994–998

Effert PJ, Beniers AJ, Tamimi Y, Handt S, Jakse G (2004) Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Research 24:3057–3063

Elsasser-Beile U, Wolf P, Gierschner D, Buhler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66:1359–1370

Evangelista L, Cervino AR, Guttilla A, Zattoni F, Cuccurullo V, Mansi L (2015) F-18-fluoromethylcholine or F-18-fluoroethylcholine pet for prostate cancer imaging: which is better? A literature revision. Nuclear Medicine and Biology 42:340–348

Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL (2011) Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America 108:9578–9582

Foss CA, Mease RC, Fan H, Wang YC, Ravert HT, Dannals RF, Olszewski RT, Heston WD, Kozikowski AP, Pomper MG (2005) Radiolabeled small-molecule ligands for prostate-specific membrane antigen: In vivo imaging in experimental models of prostate cancer. Clinical Cancer Research 11:4022–3028

Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T, Meyer GJ, Karstens JH, Knapp WH, Boerner AR (2003) Positron emission tomography with C-11-acetate and F-18-FDG in prostate cancer patients. European Journal of Nuclear Medicine and Molecular Imaging 30, 607–611

Geworski L, Knoop BO, de-Cabrejas ML, Knapp WH, Munz DL (2000) Recovery correction for quantitation in emission tomography: a feasibility study. Eur J Nucl Med 27(2):161–169

Ghosh A, Heston WDW (2004) Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. Journal of Cellular Biochemistry 91:528–539

Glatting G, Kletting P, Reske SN, Hohl K, Ring C (2007) Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test. Med Phys 34 (11):4285–3292

Glatting G, Mottaghy FM, Baune A, Sommer TF, Landwehrmeyer GB, Reske SN (2004) Improving binding potenzial analysis in [¹¹C]raclopride PET studies using cluster analysis. Med Phys 31 (4):902–906

Glatting G, Werner C, Reske SN, Bellemann ME (2003) ROC analysis for assessment of lesion detection performance in 3D PET: Influence of reconstruction algorithms. Med Phys 30 (9):2315–2319

Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von-Schulthess GK (2002) PET-CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging 29 (3):351–360

Gourni E, Del Pozzo L, Kheirallah E, Smerling C, Waser B, Reubi JC, Paterson BM, Donnelly PS, Meyer PT, Maecke HR (2015) Copper-64 labeled macrobicyclic sarcophagine coupled to a GRP receptor antagonist shows great promise for PET imaging of prostate cancer. Molecular Pharmaceutics 12:2781–2790

Gunn RN, Gunn SR, Cunningham VJ (2001) Positron emission tomography compartmental models. J Cereb Blood Flow Metab 21 (6):635–652

Gunn RN, Gunn SR, Turkheimer FE, Aston JA, Cunningham VJ (2002) Positron emission tomography compartmental models: a basis pursuit strategy for kinetic modeling. J Cereb Blood Flow Metab 22 (12):1425–1439

Haffner MC, Kronberger IE, Ross JS, Sheehan CE, Zitt M, Muhlmann G, Ofner D, Zelger B, Ensinger C, Yang XMJ, Geley S, Margreiter R, Bander NH (2009) Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human Pathology 40:1754–1761

Haseman MK, Rosenthal SA, Polascik TJ (2000) Capromab pendetide imaging of prostate cancer. Cancer Biotherapy and Radiopharmaceuticals 15:131–140

Herman GT, Lent A (1976) Iterative reconstruction algorithms. Comput Biol Med 6 (4):273–294

Herzog H (2012) PET/MRI: Challenges, solutions and perspectives. Z Med Phys 22 (4):281–298. doi:http://dx.doi.org/10.1016/j.zemedi.2012.07.003

Herzog H, Lerche C (2016) Advances in Clinical PET/MRI Instrumentation. PET Clinics 11 (2):95–103. doi:10.1016/j.cpet.2015.09.001

Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M (1999) Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. European Urology 36:31–35

Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS (2010) Zr–89-DFO-J591 for ImmunoPET of prostate-specific membrane antigen Expression In Vivo. Journal of Nuclear Medicine 51:1293–1300

Huang S-C, Phelps ME (1986a) Parameter estimation in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 347–390

Huang S-C, Phelps ME (1986b) Principles of tracer kinetic modeling in positron emission tomography. In: Phelps ME, Mazziotta J, Schelbert H (Hrsg) Positron emission tomography and autoradiography: Principles and applications for the brain and heart. Raven Press, New York, S 287–346

Igerc I, Kohlfurst S, Gallowitsch HJ, Matschnig S, Kresnik E, Gomez-Segovia I, Lind P (2008) The value of F-18-choline PET-CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 35:976–983

International Commission on Radiation Units and Measurements (1996) ICRU Report 54. Medical Imaging – The Assessment of Image Quality. ICRU Reports., Bethesda, Maryland 20814, USA

Iriarte A, Marabini R, Matej S, Sorzano COS, Lewitt RM (2016) System models for PET statistical iterative reconstruction: A review. Computerized Medical Imaging and Graphics 48:30–38. doi:http://dx.doi.org/10.1016/j.compmedimag.2015.12.003

Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW (1994) Expression of the prostate-specific membrane antigen. Cancer Research 54:1807–1811

Jadvar H (2011) prostate cancer: PET with F-18-FDG, F-18- or C-11-Acetate, and F–18- or C-11-Choline. Journal of Nuclear Medicine 52, 81–89

Jadvar H, Chen K, Ukimura O (2015) Targeted Prostate Gland Biopsy With Combined Transrectal Ultrasound, mpMRI, and ¹⁸F-FMAU PET-CT. Clinical Nuclear Medicine 40, E426-E428

Jadvar H, Ya LP, Par RLZB, Che K, Hughe L, Kouh A, Cont P (2012) [F-18]-2’-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (F–18-FMAU) in prostate cancer: Initial Preclinical Observations. Molecular Imaging 11:426–332

Jana S, Blaufox MD (2006) Nuclear medicine studies of the prostate, testes, and bladder. Seminars in Nuclear Medicine 36, 51–72

Joshua WC, Craig SL (2016) Advances in coincidence time resolution for PET. Phys Med Biol 61 (6):2255–2264

Kahkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, Luoto P, Sipila HJ, Tolvanen T, Alanen K, Silen J, Kallajoki M, Roivainen A, Schafer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H (2013) In vivo imaging of prostate cancer using [Ga-68]-labeled bombesin analog BAY86–7548. Clinical Cancer Research 19:5434–5443

Kairemo K, Rasulova N, Partanen K, Joensuu T (2014) Preliminary clinical experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic acid (anti-(18)F-FACBC) PET-CT imaging in prostate cancer patients. Biomed Research International:305182

Kato T, Tsukamoto E, Kuge Y, Takei T, Shiga T, Shinohara N, Katoh C, Nakada K, Tamaki N (2002) Accumulation of [C-11]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 29:1492–1495

Kelloff GJ, Choyke P, Coffey DS (2009) Challenges in Clinical prostate cancer: Role of Imaging. American Journal of Roentgenology 192:1455–1470

Keyes JW (1995) SUV: Standard uptake or silly useless value? J Nucl Med 36 (10):1836–1839

Kinahan PE, Townsend DW, Beyer T, Sashin D (1998) Attenuation correction for a combined 3D PET-CT scanner. Med Phys 25 (10):2046–2053

Kitajima K, Murphy RC, Nathan MA (2013) Choline PET-CT for imaging prostate cancer: an update. Annals of Nuclear Medicine 27:581–591

Kletting P, Schimmel S, Kestler HA, Hänscheid H, Luster M, Fernández M, Bröer JH, Nosske D, Lassmann M, Glatting G (2013) Molecular radiotherapy: The NUKFIT software for calculating the time-integrated activity coefficient. Med Phys 40 (10):102504

Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF (2015) ⁶⁸Ga-68-PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. European Journal of Nuclear Medicine and Molecular Imaging 42:210–214

Kusumi T, Koie T, Tanaka M, Matsumoto K, Sato F, Kusumi A, Ohyama C, Kijima H (2008) Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathology International 58:687–694

Langsteger W, Kunit T, Haim S, Nader M, Valencia R, Lesche R, Sega W, Piert M, Loidl W, Beheshti M (2012) BAY 1075553 PET-CT in the assessment of prostate cancer: safety, tolerability and biodistribution – phase I first in human study results. Journal of Nuclear Medicine 53:1125

Lapi SE, Wahnishe H, Pham D, Wu LY, Nedrow-Byers JR, Liu TC, Vejdani K, VanBrocklin HF, Berkman CE, Jones EF (2009) Assessment of an F-18-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Journal of Nuclear Medicine 50:2042–2048

Lapidus RG, Tiffany CW, Isaacs JT, Slusher BS (2000) Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 45:350–354

Larson SM, Morris M, Gunther I, Beattie B, Humm JL, Akhurst TA, Finn RD, Erdi Y, Pentlow K, Dyke J, Squire O, Bornmann W, McCarthy T, Welch M, Scher H (2004) Tumor localization of 16 beta-F-18-fluoro–5 alpha-dihydrotestosterone vs. F–18-FDG in patients with progressive, metastatic prostate cancer. Journal of Nuclear Medicine 45:366–373

Lesche R, Kettschau G, Gromov AV, Bohnke N, Borkowski S, Monning U, Hegele-Hartung C, Dohr O, Dinkelborg LM, Graham K (2014) Preclinical evaluation of BAY 1075553, a novel F-18-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 41:89–101

Lewellen TK (1998) Time-of-flight PET. Semin Nucl Med 28 (3):268–275. doi:10.1016/s0001–2998(98)80031–7

Li ZB, Wu ZH, Chen K, Ryu EK, Chen XY (2008) F-18-labeled BBN-RGD heterodimer for prostate cancer imaging. Journal of Nuclear Medicine 49:453–361

Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Research 57:3629–3634

Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Research 58:4055–3060

Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK (2001) Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 57:108–111

Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. prostate cancer and Prostatic Diseases 9:230–234

Liu ZF, Li ZB, Cao QZ, Liu SL, Wang F, Chen XY (2009a) Small-animal PET of tumors with (64Cu)-labeled RGD-bombesin heterodimer. Journal of Nuclear Medicine 50:1168-1177

Liu ZF, Niu G, Wang F, Chen XY (2009b) Ga-68-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. European Journal of Nuclear Medicine and Molecular Imaging 36:1483–1494

Liu ZF, Yan YJ, Chin FT, Wang F, Chen XY (2009c) Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using F–18-labeled PEGylated RGD-Bombesin Heterodimer F-18-FB-PEG(3)-Glu-RGD-BBN. Journal of Medicinal Chemistry 52:425–332

Lottes G, Schober O (2000) Zur Geschichte der Nuklearmedizin – eine chronologische Darstellung der Ursprünge aus Naturwissenschaft, Technik und Medizin. Z Med Phys 10 (4):225–234

Lupold SE, Hicke BJ, Lin Y, Coffey DS (2002) Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Research 62:4029–3033

Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. Journal of Cellular Physiology 202, 654–662

Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G (2009) Heterogeneity of prostate-specific membrane antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathology & Oncology Research 15:167–172

Mansi R, Wang XJ, Forrer F, Kneifel S, Tamma ML, Waser B, Cescato R, Reubi JC, Maecke HR (2009) Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides. Clin Cancer Res 15:5240–5249

Mansi R, Wang XJ, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97–107

Mease RC, Dusich CL, Foss CA, Ravert HT, Dannals RF, Seidel J, Prideaux A, Fox JJ, Sgouros G, Kozikowski AP, Pomper MG (2008) N-[N-[(S)–1,3-dicarboxypropyl]carbamoyl]-3-[F-18]fluorobenzyl-L-cysteine, [F-18]DCFBC: A new imaging probe for prostate cancer. Clinical Cancer Research 14:3036–3043

Mehranian A, Arabi H, Zaidi H (2016) Vision 20/20: Magnetic resonance imaging-guided attenuation correction in PET/MRI: challenges, solutions, and opportunities. Medical Physics 43 (3):1130–1155. doi:doi:http://dx.doi.org/10.1118/1.4941014

Mesters JR, Barinka C, Li WX, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. Embo Journal 25:1375–1384

Mesters JR, Henning K, Hilgenfeld R (2007) Human glutamate carboxypeptidase II inhibition: structures of GCPII in complex with two potent inhibitors, quisqualate and 2-PMPA. Acta Crystallographica Section D-Biological Crystallography 63:508–513

Metz CE (1978) Basic principles of ROC analysis. Semin Nucl Med 8 (4):283–298

Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH (2004) Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancerJournal of Clinical Oncology 22:2522–2531

Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, Huland H, Bokemeyer C, Yekebas E, Dierlamm J, Balabanov S, Kilic E, Wilczak W, Simon R, Sauter G, Schlomm T (2011) High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate 71:281–288

Molina-Duran F, Dinter D, Schoenahl F, Schoenberg SO, Glatting G (2014) Dependence of image quality on acquisition time for the PET-CT Biograph mCT. Z Med Phys 24 (1):73–79. doi:10.1016/j.zemedi.2013.03.002

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang RB, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015) Prospective Comparison of F-18-Fluoromethylcholine vs. Ga-68-PSMA PET-CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy. Journal of Nuclear Medicine 56:1185-1190

Nanda PK, Pandey U, Bottenus BN, Rold TL, Sieckman GL, Szczodroski AF, Hoffman TJ, Smith CJ (2012) Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 39:461–371

Nanni C, Schiavina R, Boschi S, Ambrosini V, Pettinato C, Brunocilla E, Martorana G, Fanti S (2013) Comparison of F-18-FACBC and C-11-choline PET-CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results. European Journal of Nuclear Medicine and Molecular Imaging 40:S11–S17

Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, Gentile G, Vagnoni V, Romagnoli D, Martorana G, Fanti S (2014) ¹⁸F-FACBC Compared with ¹¹C-Choline PET-CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clinical Genitourinary Cancer 12:106–110

National Electrical Manufacturers Association (2007) Performance Measurements of Positron Emission Tomographs. In: NEMA Standards Publication NU 2–2007:S 1–6

Nimmagadda S, Shield AF (2008) The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews 27:575–587

Nye JA, Schuster DM, Yu WP, Camp VM, Goodman MM, Votaw JR (2007) Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue Anti-F–18-FACBC in humans. Journal of Nuclear Medicine 48:1017–1020

Odewole OA, Oyenuga OA, Tade F, Savir-Baruch B, Nieh PT, Master V, Chen ZJ, Wang XJ, Jani AB, Bellamy LM, Halkar RK, Goodman MM, Schuster DM (2015) Reproducibility and Reliability of Anti–3-[F–18]FACBC Uptake Measurements in Background Structures and Malignant Lesions on Follow-Up PET-CT in Prostate Carcinoma: an Exploratory Analysis. Molecular Imaging and Biology 17:277–283

Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu WP, Votaw JR, Yoshida Y, Goodman MM, Ito O (2007) A preliminary study of anti–1-amino–3-F–18-fluorocyclobutyl–1-carboxylic acid for the detection of prostate cancer. Journal of Nuclear Medicine 48:46–55

Oka S, Okudaira H, Yoshida Y, Schuster DM, Goodman MM, Shirakami Y (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-C-14] cyclobutanecarboxylic acid in prostate cancer cells. Nuclear Medicine and Biology 39:109–119

Okudaira H, Nakanishi T, Oka S, Kobayashi M, Tamagami H, Schuster DM, Goodman MM, Shirakami Y, Tamai I, Kawai K (2013) Kinetic analyses of trans–1-amino–3[F–18]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nuclear Medicine and Biology 40:670–675

Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, Sadato N, Yamamoto K, Okada K (2002) C-11-acetate PET imaging of prostate cancer. Journal of Nuclear Medicine 43:181–186

Oyama N, Akino H, Suzuki Y, Kanamaru H, Ishida H, Tanase K, Sadato N, Yonekura Y, Okada K (2001) FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nuclear Medicine Communications 22, 963–969

Panebianco V, Sciarra A, Lisi D, Galati F, Buonocore V, Catalano C, Gentile V, Laghi A, Passariello R (2012) Prostate cancer: 1HMRS-DCEMR at 3 T vs. [¹⁸F]choline PET-CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). European Journal of Radiology 81:700–708

Perkins AC, Missailidis S (2007) Radiolabelled aptamers for tumour imaging and therapy. Quarterly Journal of Nuclear Medicine and Molecular Imaging 51:292–296

Perner S, Hofer MD, Kim R, Shah RB, Li HJ, Moller P, Hautmann RE, Gschwend JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Human Pathology 38:696–701

Phelps ME, Hoffman EJ, Mullani NA, Ter-Pogossian MM (1975) Application of annihilation coincidence detection to transaxial reconstruction tomography. J Nucl Med 16 (3):210–224

Pomper MG, Musachio JL, Zhang JZ, Scheffel U, Zhou Y, Hilton J, Maini A, Dannals RF, Wong DF, Kozikowski AP (2002) C-11-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALADase). Molecular Imaging 1:96–101

Preylowski V, Schlögl S, Schoenahl F, Jörg G, Samnick S, Buck AK, Lassmann M (2013) Is the Image Quality of I–124-PET Impaired by an Automatic Correction of Prompt Gammas? PLoS ONE 8 (8):e71729. doi:10.1371/journal.pone.0071729

Qi J, Leahy RM (2006) Iterative reconstruction techniques in emission computed tomography. Phys Med Biol 51 (15):541–578

Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: Concordance between biopsy and prostatectomy over 15 years. Urology 72:177–182

Ratib O, Beyer T (2011) Whole-body hybrid PET/MRI: ready for clinical use? Eur J Nucl Med Mol Imaging 38 (6):992–995

Rausch I, Cal-Gonzalez J, Dapra D, Gallowitsch H, Lind P, Beyer T, Minear G (2015) Performance evaluation of the Biograph mCT Flow PET-CT system according to the NEMA NU2–2012 standard. EJNMMI Physics 2 (1):26

Reubi JC, Fleischmann A, Waser B, Rehmann R (2011) Concomitant vascular GRP-receptor and VEGF-receptor expression in human tumors: Molecular basis for dual targeting of tumoral vasculature. Peptides 32:1457–1462

Reubi JC, Gugger M, Waser B (2002a) Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 29:855–862

Reubi JC, Maecke HR (2008) Peptide-based probes for cancer imaging. J Nucl Med 49:1735–1738

Reubi JC, Maecke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46:67s–75s

Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging 30:781–793

Reubi JC, Wenger S, Schmuckli-Maurer J, Schaer JC, Gugger M (2002b) Bombesin receptor subtypes in human cancers: Detection with the universal radioligand I–125-[D-TYR6, beta-ALA(11), PHE13, NLE14] bombesin(6–14). Clin Cancer Res 8:1139–1146

Rockey WM, Huang L, Kloepping KC, Baumhover NJ, Giangrande PH, Schultz MK (2011) Synthesis and radiolabeling of chelator-RNA aptamer bioconjugates with copper–64 for targeted molecular imaging. Bioorganic & Medicinal Chemistry 19:4080–3090

Ross JS, Sheehan CE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clinical Cancer Research 9:6357–6362

Rossi S, Graner E, Febbo P, Weinstein L, Bhattacharya N, Onody T, Bubley G, Balk S, Loda M (2003) Fatty acid synthase molecular signatures expression defines distinct in prostate cancer. Molecular Cancer Research 1, 707–715

Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB, Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease RC, Pomper MG, Cho SY (2015) F-18-DCFBC PET-CT for PSMA-based detection and characterization of primary prostate cancer. Journal of Nuclear Medicine 56:1003–1010

Ruggiero A, Holland JP, Hudolin T, Shenker L, Koulova A, Bander NH, Lewis JS, Grimm J(2011) Targeting the Internal Epitope of prostate-specific membrane antigen with Zr-89-7E11 Immuno-PET. Journal of Nuclear Medicine 52:1608–1615

Rybalov M, Ananias, HJK, Hoving, HD, van der Poel HG, Rosati S, de Jong IJ (2014) PSMA, EpCAM, VEGF and GRPR as Imaging Targets in Locally Recurrent prostate cancer after Radiotherapy. International Journal of Molecular Sciences 15:6046–6061

Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A (2016) 68Ga-PSMA–11 dynamic PET-CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging epub ahead of print 12.01.2016:1–12. doi:10.1007/s00259–015–3302–3

Salminen E, Hogg A, Binns D, Frydenberg M, Hicks R (2002) Investigations with FDG-PET scanning in prostate cancer show limited value for clinical practice. Acta Oncologica 41:425–329

Samplaski MK, Heston W, Elson P, Magi-Galluzzi C, Hansel DE (2011) Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature. Modern Pathology 24:1521–1529

Sandblom G, Sorensen J, Lundin N, Haggman M, Malmstrom PU (2006) Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology 67:996–1000

Schafer M, Bauder-Wust U, Leotta K, Zoller F, Mier W, Haberkorn U, Eisenhut M, Eder M (2012) A dimerized urea-based inhibitor of the prostate-specific membrane antigen for Ga-68-PET imaging of prostate cancer. EJNMMI Res 2

Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, Fdn PC (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446

Schiepers C, Hoh CK, Nuyts J, Seltzer M, Wu C, Huang SC, Dahlbom M (2008) ¹¹C-acetate kinetics of prostate cancer. Journal of Nuclear Medicine 49:206–215

Schlegel W, Bille J (2002) Medizinische Physik 2. Springer, Berlin Heidelberg

Schmidlin P, Doll J (1991) Implementation of iterative reconstruction in positron emission tomography. In: Information processing in medical imaging. Wiley, S 59–67

Schuster DM, Savir-Baruch B, Nieh PT, Master VA, Halkar RK, Rossi PJ, Lewis MM, Nye JA, Yu WP, Bowman FD, Goodman MM (2011) Detection of Recurrent Prostate Carcinoma with anti–1-Amino–3-F–18-Fluorocyclobutane–1-Carboxylic Acid PET-CT and In-111-Capromab Pendetide SPECT/CT. Radiology 259, 852–861

Schuster DM, Votaw JR, Nieh PT, Yu WP, Nye JA, Master V, Bowman FD, Issa MM, Goodman MM (2007) Initial experience with the radiotracer anti–1-amino–3-F–18-fluorocyclobutane–1-carboxylic acid with PET-CT in prostate carcinoma. Journal of Nuclear Medicine 48:56–63

Shao Y, Cherry SR, Farahani K, Meadors K, Siegel S, Silverman RW, Marsden PK (1997) Simultaneous PET and MR imaging. Phys Med Biol 42 (10):1965–1970

Shields AF (2006) Positron emission tomography measurement of tumor metabolism and growth: Its expanding role in oncology. Molecular Imaging and Biology 8:141–150

Silver DA, Pellicer I, Fair WR, Heston WDW, CordonCardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clinical Cancer Research 3:81–85

Slomka P, Baum R (2009) Multimodality image registration with software: state-of-the-art. Eur J Nucl Med Mol Imag 36 (0):44–55. doi:10.1007/s00259–008–0941–8

Slomka PJ, Pan T, Germano G (2016) Recent Advances and Future Progress in PET Instrumentation. Seminars in Nuclear Medicine 46 (1):5–19. doi:10.1053/j.semnuclmed.2015.09.006

Smith TAD (2000) Mammalian hexokinases and their abnormal expression in cancer. British Journal of Biomedical Science 57:170–178

Strand SE, Zanzonico P, Johnson TK (1993) Pharmacokinetic modeling. Med Phys 20 (2 Pt 2):515–527

Sun HH, Mangne TJ, Collin JM, Muzi O, Dougla K, Shield AF (2005a) Imaging DNA synthesis in vivo with F–18-FMAU and PET. Journal of Nuclear Medicine 46:292–296

Sun HH, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, Shields AF (2005b) Imaging DNA synthesis with [F-18]FMAU and positron emission tomography in patients with cancer. European Journal of Nuclear Medicine and Molecular Imaging 32:15–22

Surti S, Karp JS (2016) Advances in time-of-flight PET. Physica Medica 32 (1):12–22. doi:http://dx.doi.org/10.1016/j.ejmp.2015.12.007

Surti S, Karp JS, Freifelder R, Liu F (2000) Optimizing the performance of a PET detector using discrete GSO crystals on a continuous lightguide. IEEE Trans Nucl Sci 47:1030–1036

Surti S, Karp JS, Popescu LM, Daube-Witherspoon ME, Werner M (2006) Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 25 (5):529–538. doi:10.1109/tmi.2006.871419

Sutinen E, Nurmi M, Roivainen A, Varpula M, Tolvanen T, Lehikoinen P, Minn H (2004) Kinetics of [C-11]choline uptake in prostate cancer: a PET stydy. European Journal of Nuclear Medicine and Molecular Imaging 31:317–324

Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA, Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M, Bhatnagar A, Sgouros G, Cho SY, Pomper MG (2015) Initial evaluation of [F–18]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Molecular Imaging and Biology 17:565–574

Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, Petrillo K, Parmar S, Nanus DM, Bander NH (2010) Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116:1075–1083

Tavitian B, Duconge F, Boisgard R, Dolle F (2009) In vivo imaging of oligonucleotidic aptamers. Methods Mol Biol 535:241–259

Ter-Pogossian MM, Mullani NA, Ficke DC, Markham J, Snyder DL (1981) Photon time-of-flight-assisted positron emission tomography. J Comput Assist Tomogr 5 (2):227–239. doi:10.1097/00004728–198104000–00014

Troyer JK, Beckett ML, Wright GL (1995a) Detection and characterization of the prostate-specific membrane antigen (Pmsa) in tissue-extracts and body-fluids. International Journal of Cancer 62:552–558

Troyer JK, Beckett ML, Wright GL (1997) Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30:232–242

Troyer JK, Feng Q, Beckett ML, Wright GL Jr (1995b) Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen. Urol Oncol 1:29–37

Turkbey B, Mena E, Shih J, Pinto PA, Merino MJ, Lindenberg ML, Bernardo M, McKinney YL, Adler S, Owenius R, Choyke PL, Kurdziel KA (2014) Localized prostate cancer detection with F-18 FACBC PET-CT: comparison with MR imaging and histopathologic analysis. Radiology 270:849–856

Umbehr MH, Muntener M, Hany T, Sulser T, Bachmann LM (2013) The Role of 11-C-Choline and 18-F-Fluorocholine positron emission tomography (PET) and PET-CT in prostate cancer: a systematic review and meta-analysis. European Urology 64:106–117

Vali R, Loidl W, Pirich C, Langesteger W, Beheshti M (2015) Imaging of prostate cancer with PET-CT using (18)F-Fluorocholine. Am J Nucl Med Mol Imaging 5:96–108

Vandenberghe S, Daube-Witherspoon ME, Lewitt RM, Karp JS (2006) Fast reconstruction of 3D time-of-flight PET data by axial rebinning and transverse mashing. Phys Med Biol 51 (6):1603–1621. doi:10.1088/0031–9155/51/6/017

Vandenberghe S, Mikhaylova E, D’Hoe E, Mollet P, Karp JS (2016) Recent developments in time-of-flight PET. EJNMMI Phys 3 (1):1–30. doi:10.1186/s40658–016–0138–3

Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H (2014) Bone Metastases in Castration-Resistant prostate cancer: Associations between Morphologic CT Patterns, Glycolytic Activity, and Androgen Receptor Expression on PET and Overall Survival. Radiology 271:220–229

Viola-Villegas NT, Sevak KK, Carlin SD, Doran MG, Evans HW, Bartlett DW, Wu AM, Lewis JS (2014) Noninvasive imaging of PSMA in prostate tumors with Zr-89-labeled huJ591 engineered antibody fragments: the faster alternatives. Molecular Pharmaceutics 11:3965–3973

Visser EP, Boerman OC, Oyen WJG (2010) SUV: From Silly Useless Value to Smart Uptake Value. J Nucl Med 51 (2):173–175. doi:10.2967/jnumed.109.068411

Wan H, Olive P, Na L, Wan SY, Wan Z, Rhi JK, Zhan RW, Hill DL (2002) Radiolabeled 2’-fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2’-fluoro-5-methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemotherapy and Pharmacology 49:419–324

Wang WL, Tavora F, Sharma R, Eisenberger M, Netto GJ (2009) PSMA expression in Schwannoma: A potenzial clinical mimicker of metastatic prostate carcinoma. Urologic Oncology-Seminars and Original Investigations 27:525–528

Wieser G, Mansi R, Grosu AL, Schultze-Seemann W, Dumont-Walter RA, Meyer PT, Maecke HR, Reubi JC, Weber WA (2014) Positron Emission Tomography (PET) imaging of prostate cancer with a Gastrin releasing peptide receptor antagonist – from mice to men. Theranostics 4:412–319

Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334

Wright GL Jr, Haley C, Beckett ML, Schellhammer PF (1995) Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol 1:18–28

Wynant GE, Murphy GP, Horoszewicz JS, Neal CE, Collier BD, Mitchell E, Purnell G, Tyson I, Heal A, Abdelnabi H, Winzelberg G (1991) Immunoscintigraphy of prostatic cancer - preliminary-results with in-111-labeled monoclonal-antibody 7e11-C5.3 (Cyt–356). Prostate 18:229–241

Yan YJ, Chen K, Yang M, Sun XL, Liu SL, Chen XY (2011) A new F-18-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids 41:439–347

Yao V, Bacich DJ (2006) Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 66:867–875

Yao V, Berkman CE, Choi JK, O’Keefe DS, Bacich DJ (2010) Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. Prostate 70:305–316

Yao V, Parwani A, Maier C, Heston WD, Bacich DJ (2008) Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Research 68:9070–9077

Yu, EY, Muzi M, Hackenbracht JA, Rezvani BB, Link JM, Montgomery RB, Higano CS, Eary JF, Mankoff DA (2011) C11-Acetate and F–18 FDG PET for Men With prostate cancer Bone Metastases Relative Findings and Response to Therapy. Clinical Nuclear Medicine 36:192–198

Zanzonico PB, Finn R, Pentlow KS, Erdi Y, Beattie B, Akhurst T, Squire O, Morris M, Scher H, McCarthy T, Welch M, Larson SM, Humm JL (2004) PET-based radiation dosimetry in man of F-18-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer. Journal of Nuclear Medicine 45:1966–1971

Zhou J, Neale JH, Pomper MG, Kozikowski AP (2005) NAAG peptidase inhibitors and their potenzial for diagnosis and therapy. Nature Reviews Drug Discovery 4:1015–1026

Zhu L, Niu G, Fang X, Chen X (2010) Preclinical molecular imaging of tumor angiogenesis. Quarterly Journal of Nuclear Medicine and Molecular Imaging 54:291–308

Ziegler SI (2007) Instrumentierung: SPECT, PET, PET-CT. In: Krause B-J, Schwaiger M, Buck AK (Hrsg) Nuklearmedizinische Onkologie. ecomed, 1. Aufl. Hüthig Jehle Rehm, Landsberg, S 17–24

Ziegler SI, Pichler BJ (2000) Neue technische Entwicklungen in der Nuklearmedizin. Z Med Phys 10 (4):237–245

Titel: Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie
verfasst von: Prof. Dr. Gerhard Glatting
PD Dr. rer.nat. Carmen Wängler
Prof. Dr. rer. nat. Björn Wängler
Verlag: Springer Berlin Heidelberg
Buch: MR- und PET-Bildgebung der Prostata
Print ISBN: 978-3-662-50467-3

Electronic ISBN: 978-3-662-50468-0

Copyright-Jahr: 2017
DOI: https://doi.org/10.1007/978-3-662-50468-0_2

Neu im Fachgebiet Radiologie

Hölzerner Fremdkörper in der Orbita? Zuerst eine CT!

09.03.2025
Erkrankungen der Orbita
Nachrichten

Besteht der Verdacht, dass ein Fremdkörper aus Holz in den Orbitalraum eingedrungen ist, spielt die Bildgebung eine entscheidende diagnostische Rolle. Was von CT und MRT zu erwarten ist, hat ein chinesisches Radiologenteam untersucht.

Diagnostik von Rippenfrakturen: KI schlägt Radiologen

07.03.2025
Rippenfraktur
Nachrichten

Mensch gegen Maschine: Beim Erkennen von Rippenfrakturen in Röntgen- und CT-Aufnahmen entschied sich dieses Duell zugunsten der künstlichen Intelligenz (KI). Die Algorithmen zeigten eine höhere Sensitivität als ihre menschlichen Kollegen.

Ärztinnen überholen Ärzte bei Praxisgründungen

Praxis und Beruf
Nachrichten

Bei Praxisgründungen haben inzwischen die Frauen deutlich die Nase vorn: Seit zehn Jahren wagen laut apoBank mehr Ärztinnen als Ärzte den Schritt in die Selbstständigkeit. In puncto Finanzierung sind sie aber vorsichtiger als die männlichen Kollegen.

Ambulante Behandlung darf länger dauern als stationäre

Recht für Ärzte
Nachrichten

Ambulante Behandlungen haben Vorrang vor stationären - auch wenn diese läner dauern. Das hat das Bundessozialgericht klargestellt. Konkret ging es um Liposuktionen der Ober- und Unterschenkel.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen